New mRNA Vaccine Reduces Melanoma Risk by 42%

Merck and Moderna’s personalized mRNA cancer vaccine, known as intismeran, has demonstrated a notable capacity to reduce the risk of melanoma recurrence or death. During a phase 3 trial involving 1,137 patients, researchers found that combining intismeran with pembrolizumab led to a 42% reduction in risk compared to using pembrolizumab on its own. These findings, presented at the European Society for Medical Oncology (ESMO) congress between October 22 and 26, 2026, represent a significant step forward in oncological therapy.

This innovation is rooted in the rise of personalized medicine, which seeks to tailor treatments to the specific genetic characteristics of a patient's disease. The vaccine works by targeting as many as 34 neoantigens identified within an individual's tumor, offering a bespoke alternative to standard therapies that have historically struggled to prevent recurrence. The trial highlights how mRNA technology, which became widely known during the COVID-19 pandemic, is now being adapted to transform the way other serious illnesses are treated.

The study was conducted across 157 sites worldwide, reflecting a broad effort to test the vaccine’s effectiveness across different populations. Data shows that two years after surgery, 82% of the patients who received the vaccine remained free of recurrence, while only 70% of those on standard therapy reached the same milestone. Such a margin suggests that personalized vaccines could notably improve the long-term prospects for those diagnosed with melanoma.

Beyond the immediate results for participants, the trial points toward a broader shift in how cancer is managed. The success of intismeran suggests that the future of oncology may lie in these highly specific, individual therapies. Furthermore, the application of mRNA technology in this context may provide a blueprint for developing vaccines for other types of cancer, potentially altering the landscape of public health and modern medicine.

As the trial data enters regulatory review, the medical community is moving closer to the potential approval and wider availability of this personalized mRNA treatment. Ongoing research in the field points toward a future where cancer care is increasingly precise and responsive to the needs of the individual. The global reach of intismeran may eventually lead to new ways of addressing melanoma and other cancers, offering a constructive path forward for both patients and healthcare providers.